-
Tongjitang Chinese Medicines Company Shareholders Vote to Approve Merger
Thursday, March 31, 2011 - 9:07am | 113Tongjitang Chinese Medicines Company (NYSE: TCM), announced today that, at an extraordinary general meeting held today, the Company's shareholders voted in favor of the proposal to adopt the previously disclosed Agreement and Plan of Merger, dated as of October 29, 2010, as amended on February 21...
-
VICTRELIS, Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control
Thursday, March 31, 2011 - 8:35am | 153Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported that final results from a Phase III study of VICTRELIS, its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a and ribavirin therapy demonstrated significantly higher sustained...
-
Jefferies Downgrades BMY To Hold
Thursday, March 31, 2011 - 8:28am | 82Jefferies has downgraded Bristol-Myers Squibb (NYSE: BMY) from a Buy Rating to a Hold Rating. According to Jefferies, "The US approval of Yervoy has brought the stock price within 8% of our price target. With a heavy launch schedule ahead and pricing pressure compressing margins we see little room...
-
Benzinga's Top Upgrades (CAVM, EMR, ARMH, BMY)
Thursday, March 31, 2011 - 8:20am | 136Cavium Networks Inc (NASDAQ: CAVM) was upgraded by Auriga from "hold" to "buy." CAVM's shares closed at $42.93 yesterday. Cavium Networks' trailing-twelve-month ROE is 18.99%. Deutsche Bank upgraded Emerson Electric Company (NYSE: EMR) from “hold” to “buy.” EMR's shares closed at $57.41 yesterday...
-
Oppenheimer Anticipates Positive OPTR Vote From FDA
Thursday, March 31, 2011 - 8:04am | 148Oppenheimer has released a report on the upcoming FDA advisory panel meeting for Optimer Pharmaceuticals (NASDAQ: OPTR). According to the report, "We are previewing the FDA advisory panel meeting on April 5th, when panel members will vote on approval of OPTR's antibiotic Fidaxomicin for treatment...
-
Jefferies Downgrades Bristol-Myers Squibb To Hold
Thursday, March 31, 2011 - 7:04am | 23Jefferies & Company has downgraded Bristol-Myers Squibb (NYSE: BMY) from Buy to Hold and maintains its $28.50.
-
Jefferies Ups BMY To Hold
Thursday, March 31, 2011 - 5:57am | 41Analysts at Jefferies upgrade Bristol Myers Squibb Co (NYSE: BMY) from “underperform” to “hold.” BMY shares fell 0.15% to close at $26.47 yesterday. More Analyst Ratings here
-
Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The Highest Revenue (PRX, CPD, HITK, AKRX)
Thursday, March 31, 2011 - 12:41am | 133Below are the top small-cap drugs-generic stocks on the NYSE, the NASDAQ and the AMEX in terms of revenue. The trailing-twelve-month revenue at Pharmaceutical Companies (NYSE: PRX) is $1.01 billion. PRX's ROE for the same period is 16.46%. The trailing-twelve-month revenue at Caraco...
-
Jump on Jobs 03-30-2011
Wednesday, March 30, 2011 - 8:47pm | 864Cusick's Corner The market continued to chop its way higher into the After Hours and the strength continued to be wide spread. Most notably the Small Caps, IWM & RUT, were the leaders and traders like to see these higher beta stocks to be on the move. Market watchers will be focused on Ireland...
-
Red Flag – Copper Pulling Back 03-30-2011
Wednesday, March 30, 2011 - 3:27pm | 964Cusick's Corner The bulls are on the loose and I am not one to get in front of a raging bull. Big Money, those managers who washed their hands of this market 10 sessions ago are feeling enough remorse and are back in, more so than the typical window dressing that we typically we see at month's...
-
Hapoalim Securities Reiterates Buy Rating on Amarin Corporation (AMRN)
Wednesday, March 30, 2011 - 2:17pm | 157Goldman Sachs is out with a research report this morning, where it reiterates its Buy rating on Amarin Corporation (NASDAQ: AMRN); it has a $12.00 price target on the stock. The HS analysts cited GlaxoSmithKline's announcement that it has settled with Apotex regarding the Lovaza (omega-3-acid...
-
Calls Purchased as Somaxon Pharmaceuticals Pops (SOMX)
Wednesday, March 30, 2011 - 12:59pm | 123Shares of Somaxon Pharmaceuticals (NASDAQ: SOMX) are higher on the session by 5.88%, currently trading at $2.95. The stock has been moving largely lower over the past six months and is currently trading below the 200-day moving average. Options traders are buying calls on the name today. A short...
-
Cephalon Stocks Surge After Valeant Makes Bid Public (CEPH, VRX)
Wednesday, March 30, 2011 - 12:25pm | 265Cephalon (NASDAQ: CEPH) stock rose $16.45 this morning, stopping at $75.20 a share after a hostile takeover bid of approximately $5.7 billion from Valeant Pharmaceuticals International (NYSE: VRX). Cephalon's surge is Nasdaq's biggest intraday gain since April 2000. Cephalon's surge of...
-
Puts Purchased on Elan Corporation (ELN)
Wednesday, March 30, 2011 - 11:47am | 121Shares of Elan Corporation (NYSE: ELN) are higher on the session by 1.18%, currently trading at $6.88. The stock has been moving largely higher over the past six months and is currently trading above the 50-day moving average. Options traders are buying puts on the name today. A short while ago...
-
Somaxon Pharmaceuticals Rumor on Patents: Up 8% (SOMX)
Wednesday, March 30, 2011 - 11:11am | 68Rumors circulating from speculative sources that Somaxon Pharma (NASDAQ: SOMX) has had some patents approved. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your...